Glomerular diseases (GDs) associated with chronic lymphocytic leukemia (CLL) are unusual [1]. Th e many causes of renal failure in patients with CLL include immune-complex deposition, hyperkalemia, amyloid deposition, sepsis, hemoglobinuria in the setting of hemolysis, uric acid nephropathy caused by tumor lysis syndrome (TLS) and therapy related complications. Th e most common clinical manifestations of these nephropathies include proteinuria, hematuria, electrolyte abnormalities (hyperkalemia) and progressive renal failure [2,3]. Th e most frequent GD associated with CLL is membranoproliferative glomerulonephritis (MPGN) (45%), followed by membranous glomerulonephritis (MGN) (20%), with occasional reports of proliferative, minimal change disease, immunotactoid glomerulopathy (ITG), and amyloid or